ERBB2 and breast carcinoma: Compared to HER2-overexpressing and triple-negative cancers, ER-positive breast cancers exhibited more mid- to long-term relapses and acquired ESR1 mutations, resulting in the ligand-independent and constitutive activation of the ER that is believed to play a major role in late recurrence and endocrine therapy resistance (39).